Chief Investigators: Palmer, Miller, Fahey. CPA MRFF $498K.
Aims: Determine if antenatal maternal melatonin supplementation, improves neurodevelopmental outcomes at 2 years for survivors of fetal growth restriction (FGR) in 336 women with a singleton FGR pregnancy.
Mechanism: Antioxidant, anti-inflammatory and anti-apoptotic.
New Knowledge: First RCT of melatonin in FGR to assess neurodevelopment, n=258/300 recruited.
